BACKGROUND: Fetal death is an obstetrical syndrome that annually affects 2.4 to 3 million pregnancies worldwide, including more than 20,000 in the United States each year. Currently, there is no test available to identify patients at risk for this pregnancy complication. OBJECTIVE: We sought to determine if maternal plasma concentrations of angiogenic and antiangiogenic factors measured at 24-28 weeks of gestation can predict subsequent fetal death. STUDY DESIGN: A case-cohort study was designed to include 1000 randomly selected subjects and all remaining fetal deaths (cases) from a cohort of 4006 women with a singleton pregnancy, enrolled at 6-22 weeks of gestation, in a pregnancy biomarker cohort study. The placentas of all fetal deaths were histologically examined by pathologists who used a standardized protocol and were blinded to patient outcomes. Placental growth factor, soluble endoglin, and soluble vascular endothelial growth factor receptor-1 concentrations were measured by enzyme-linked immunosorbent assays. Quantiles of the analyte concentrations (or concentration ratios) were estimated as a function of gestational age among women who delivered a live neonate but did not develop preeclampsia or deliver a small-for-gestational-age newborn. A positive test was defined as analyte concentrations (or ratios) <2.5th and 10th centiles (placental growth factor, placental growth factor/soluble vascular endothelial growth factor receptor-1 [angiogenic index-1] and placental growth factor/soluble endoglin) or >90th and 97.5th centiles (soluble vascular endothelial growth factor receptor-1 and soluble endoglin). Inverse probability weighting was used to reflect the parent cohort when estimating the relative risk. RESULTS: There were 11 fetal deaths and 829 controls with samples available for analysis between 24-28 weeks of gestation. Three fetal deaths occurred <28 weeks and 8 occurred 28 weeks of gestation. The rate of placental lesions consistent with maternal vascular underperfusion was 33.3% (1/3) among those who had a fetal death <28 weeks and 87.5% (7/8) of those who had this complication 28 weeks of gestation. The maternal plasma angiogenic index-1 value was <10th centile in 63.6% (7/11) of the fetal death group and in 11.1% (92/829) of the controls. The angiogenic index-1 value was <2.5th centile in 54.5% (6/11) of the fetal death group and in 3.7% (31/829) of the controls. An angiogenic index-1 value <2.5th centile had the largest positive likelihood ratio for predicting fetal death >24 weeks (14.6; 95% confidence interval, 7.7e27.7) and a relative risk of 29.1 (95% confidence interval, 8.8e97.1), followed by soluble endoglin >97.5th centile and placental growth factor/soluble endoglin <2.5th, both with a positive likelihood ratio of 13.7 (95% confidence interval, 7.3e25.8) and a relative risk of 27.4 (95% confidence interval, 8.2e91.2). Among women without a fetal death whose plasma angiogenic index-1 concentration ratio was <2.5th centile, 61% (19/31) developed preeclampsia or delivered a small-for-gestationalage neonate; when the 10th centile was used as the cut-off, 37% (34/92) of women had these adverse outcomes. CONCLUSION: (1) A maternal plasma angiogenic index-1 value <2.5th centile (0.126) at 24-28 weeks of gestation carries a 29-fold increase in the risk of subsequent fetal death and identifies 55% of subsequent fetal deaths with a false-positive rate of 3.5%; and (2) 61% of women who have a false-positive test result will subsequently experience adverse pregnancy outcomes.
Introduction
Fetal death is an obstetrical syndrome 1, 2 caused by multiple etiologies rather than the end stage of a single disease process. [3] [4] [5] [6] This syndrome affected 23, 595 pregnancies in the United States 7 in 2013; and according to the World Health Organization, an estimated 2.6 million fetal deaths occurred globally during the third trimester. 8, 9 The most common type of fetal death is unexplained stillbirth, [10] [11] [12] [13] which comprises a progressively larger proportion of all fetal deaths as pregnancy advances. This category of fetal death accounts for approximately 20% of all cases >20 weeks of gestation and for about 40% of all cases at term, [10] [11] [12] [13] [14] [15] while infection and congenital anomalies cause most early fetal deaths (<28 weeks of gestation). [16] [17] [18] [19] Placental causes leading to fetal death, eg, placental vascular underperfusion that results in an impaired supply of nutrients to the fetus, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] abruptio placentae, [36] [37] [38] and placental senescence that has been implicated as a mechanism of fetal death at term, 22 are more frequent >26 weeks of gestation.
group of vascular lesions, including villous infarcts, syncytial knots, villous agglutination, increased intervillous fibrin deposition, distal villous hypoplasia, persistent muscularization of the basal plate arteries, and mural hypertrophy of the decidual arterioles, as well as acute atherosis of the basal plate and decidual arteries. [39] [40] [41] [42] [43] The frequency and burden of placental vascular lesions of malperfusion is reflected in the maternal plasma by an imbalance between the concentration of angiogenic (placental growth factor [PlGF] ) and antiangiogenic (soluble vascular endothelial growth factor receptor [sVEGFR]-1 and soluble endoglin [sEng]) factors. 44 Several investigators [45] [46] [47] have characterized the changes in the plasma concentrations of angiogenic and antiangiogenic factors in women who subsequently had a fetal death, demonstrating that, from 20 weeks of gestation, these patients had a lower maternal plasma PlGF and higher sEng and sVEGFR-1 concentrations than women with a normal pregnancy. 45 Additionally, a maternal plasma PlGF/sVEGFR-1 concentration ratio (angiogenic index-1) of <0.12 multiple of the median at 30-34 weeks of gestation in normal pregnancyewhich corresponds to the 5th-6th centile of the distributione identified 4 of 5 fetal deaths that occurred later in pregnancy. 48 Given that an imbalance in angiogenic and antiangiogenic factors reflects the presence and burden of placental vascular lesions of malperfusion 44 that have been proposed to be the leading cause of fetal death in the late second and third trimesters until term, 14 we sought to validate and extend these findings by determining whether plasma angiogenic index-1 at 24-28 weeks of gestation could be used as a biomarker to identify patients at risk for a subsequent fetal death.
Materials and Methods

Study design and participants
This was a case-cohort study. We randomly selected 1000 patients from a cohort of 4006 pregnant women enrolled in a longitudinal study previously reported by our group. 44 The remaining women in the original cohort who had a fetal death, but were not selected in the random sample of 1000 women, were subsequently added to the case cohort. Women who had multiple gestations or any of the following conditions at the time of enrollment were excluded from this study: active vaginal bleeding; severe maternal morbidity (ie, renal insufficiency, congestive heart disease, and chronic respiratory insufficiency); chronic hypertension requiring medication; asthma requiring systemic steroids; requirement of antiplatelet or nonsteroidal antiinflammatory drugs; active hepatitis; or fetal chromosomal abnormalities and congenital anomalies. All study participants provided written informed consent and were followed up until delivery. 
Clinical definitions
The following definitions were used in this study: 1) Fetal death: diagnosed as the death of the fetus >20 weeks of gestation and confirmed by ultrasound examination. 49 2) Preeclampsia: diagnosed by the presence of systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg on at least 2 occasions, 4 hours to 1 week apart, and of proteinuria 300 mg in a 24-hour urine collection or by 1 dipstick with 1þ. 50, 51 We have used this definition after analysis from the Collaborative Perinatal Project, which was reported in detail by Friedman and Neff, 52 and the reasons described by one of the authors. 53 Moreover, the definition outlined above was the one used in our center to collect outcome information at the time the patients were recruited and delivered.
3) Small-for-gestational-age (SGA) neonate: a birthweight <10th centile for gestational age at delivery according to a US reference population. 54 4) Preterm delivery: a delivery occurring <37th week of gestation.
Sample collection and immunoassays
Patients were scheduled to donate maternal plasma in EDTA tubes at enrollment, then every 4 weeks until the 24th week of gestation, and biweekly thereafter until delivery. Samples were centrifuged and stored at e70 C. Maternal plasma concentrations of sVEGFR-1, PlGF, and sEng were measured by immunoassays (R&D Systems, Minneapolis, MN) as previously described. 55 The interassay and intraassay coefficients of variation of the assays were 3.2% and 2.9% for sVEGFR-1, 4.5% and 5.0% for sEng, and 3.8% and 4.7% for PlGF, respectively. The sensitivity of each assay was 14.6 pg/mL for sVEGFR-1, 0.04 ng/mL for sEng, and 4.8 pg/mL for PlGF. Laboratory personnel performing the assays were blinded to the clinical information.
Histologic placental examination
Placentas were examined according to standardized protocols by perinatal pathologists blinded to clinical diagnoses and obstetrical outcomes. Placental lesions consistent with maternal vascular lesions of underperfusion (now known as maternal vascular malperfusion) were diagnosed using criteria established by the Perinatal Section of the Society for Pediatric Pathology 56 and were classified as the following: (1) villous changes, which are further subdivided into abrupt onset (remote villous infarcts, recent villous infarcts), gradual onset with intermediate duration (increased syncytial knots, villous agglutination, increased intervillous fibrin), or gradual onset with prolonged duration (distal villous hypoplasia); and (2) vascular lesions (persistent muscularization of the basal plate arteries, mural hypertrophy of the decidual arterioles, acute atherosis of the basal plate arteries and/or the decidual arterioles). 40 ajog.org
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Statistical analysis
Using quantile regression, which does not assume data normality, we estimated the percentiles of maternal plasma concentration of analytes and their ratios in a subset of controls (ie, women who delivered live babies at term and did not have preeclampsia or SGA neonate). Data were first log-transformed, a standard approach to improve normality of distribution 57 and to reduce the nonlinearity of the relation between the response and gestational age at sample collection. Linear quantile regression was then used iteratively to estimate the quantiles at discrete values of gestation, in narrow windows of gestational age, over which the linear assumption holds. The resulting estimated percentiles were not smooth because they were obtained from different models (fitted to the different narrow gestational-age windows); therefore, we fitted a 5th-degree polynomial function to smooth the estimated percentiles. 48, 58 The quantile regression was performed using the quantreg package of the R open source statistical software (URL http://www.Rproject.org/). 59, 60 Positive tests were defined as analyte concentrations (or their ratios) <2.5th and 10th centiles (PlGF, PlGF/sVEGFR-1, and PlGF/sEng) or >90th and 97.5th centiles (sVEGFR-1 and sEng). Data from the 11 fetal deaths and 829 controls with available measurements were used to construct receiver operating characteristic (ROC) curves and to determine the sensitivity, specificity, and likelihood ratios (positive and negative). Likelihood ratios for a positive test result >10 and likelihood ratios for a negative test result <0.1 were taken as strong predictive evidence under most circumstances. Moderate prediction could be achieved with likelihood ratios of 5-10 and 0.1-0.2, whereas ratios <5 and >0.2 were only minimally predictive. 61 Modified Poisson regression was used to estimate relative risk (RR) with 95% confidence intervals (CI). 62 To estimate positive predictive values (PPV), negative predictive values, and RR, we weighted the data by the inverse probability of selection to reflect the parent cohort. 63 For demographic data analysis, we used a c 2 or Fisher exact test and reported proportions for categorical variables, and medians and interquartile ranges for continuous variables.
Results
There were 24 fetal deaths (0.6%, 24/ 4006): 6 were initially selected with 994 controls in the random sample of 1000 women. Following this selection process, we added the remaining 18 patients with a fetal death from the parent cohort to the cases group, reaching a total of 24 patients. Of the 24 fetal deaths, 12 were diagnosed <28 weeks, and 12 diagnosed 28 weeks of gestation. Table 1 shows the characteristics of the cases and controls. Cases were delivered at a lower median gestational age (P < .0001) and had a lower median birthweight (P < .0001). There were no significant differences between cases and controls in median maternal age and the proportion of smokers, nulliparity, or African American ethnicity.
Patients with a fetal death had a higher rate of placental lesions consistent with maternal vascular underperfusion than the remainder of the study cohort (fetal death, 58.3% [14/24] The changes in angiogenic and antiangiogenic profiles at 24-28 weeks of gestation in women with a subsequent fetal death This analysis included only patients whose blood samples were collected between 24-28 weeks of gestation. Seven women had a fetal death <24 weeks of gestation and were excluded from further analysis. Additionally, 6 patients were excluded, as samples were not available at the desired gestational-age interval.
Eleven women with a fetal death were available for further analysis; 8 had a fetal death 28 weeks and 3 of these women Figure 1 shows the changes in the maternal plasma sVEGFR-1, sEng, and PlGF concentrations, and the PlGF/sEng ratio for fetal death cases superimposed on the estimated quantiles for the controls (after excluding patients with preeclampsia and those with an SGA neonate) (see Table 2 for quantile values of all analytes and ratios). Similar data for maternal plasma angiogenic index-1 
Concentration of angiogenic and antiangiogenic factors in patients with fetal death
For each fetal death case, data for 1 sample collected at 24-28 weeks are shown. Cases without placental lesions of maternal vascular underperfusion (MVU) (triangles) and cases with MVU (circles). Lines correspond with percentiles of analytes (or ratios) (2.5th, 10th, 50th, 90th, and 97.5th centiles). Distribution of raw longitudinal data used to derive percentiles is shown using heat map; color intensity denotes frequency of data points for corresponding gestational age: A, soluble vascular endothelial growth factor receptor (sVEGFR)-1; B, soluble endoglin (sEng); C, placental growth factor (PlGF); and D, PlGF/sEng ratio. Table 3 shows the prediction performance for fetal death >24 weeks when defining a positive test based on abnormal angiogenic and antiangiogenic factor concentrations and ratios measured at 24-28 weeks of gestation. An angiogenic index-1 value <2.5th centile had the largest positive likelihood ratio (14.6; 95% CI, 7.7e27.7) and RR (29.1; 95% CI, 8.8e97.1), followed by sEng concentrations >97.5th centile and PlGF/sEng ratios <2.5th, both of which had a positive likelihood ratio of 13.7 (95% CI, 7.3e25.8) and a RR of 27.4 (95% CI, 8.2e91.2). Table 4 presents the number of cases and controls with maternal plasma angiogenic index-1 values <10th and 2.5th centiles. Using the 10th percentile cut-off, maternal plasma angiogenic index-1 had a sensitivity of 63.6% (7/11), a false-positive rate of 11.1% (92/829), and a positive likelihood ratio of 5.7. Using the 2.5th centile cut-off, maternal plasma angiogenic index-1 had a sensitivity of 54.5% (6/11), a false-positive rate of 3.7% (31/829), and a positive likelihood ratio of 14.6 ( Table 3 ). The whole range of sensitivities and corresponding false-positive rates of angiogenic index-1 is shown by the ROC curve in Figure 3 (area under the curve, 0.79; 95% CI, 0.61e0.97, P ¼ .0005).
Eight of the 11 cases had placental lesions consistent with maternal vascular underperfusion. The positive likelihood ratio of angiogenic index-1 in these 8 cases increased from 5.7 to 7.9 at the 10th centile cut-off, and from 14.6 to 20.0 at the 2.5th centile cut-off, as 3 of the 4 cases missed by a positive angiogenic index-1 at the 10th centile did not have placental lesions consistent with maternal vascular underperfusion. In other words, angiogenic index-1 identified 7 of 8 (87.58%) subsequent fetal deaths associated with placental lesions consistent with maternal vascular underperfusion (Figure 2) . The performance of the test in the detection of fetal death in patients with maternal vascular lesions of underperfusion is shown by the ROC curve in Figure 3 (area under the curve, 0.89; 95% CI 0.71e1.00, P ¼ .00007).
The risk of fetal death in patients with abnormal angiogenic index-1
In the tested cohort in which the prevalence of fetal death >24 weeks was 1.3% (11/840), 7% of women who had a positive angiogenic index-1 value at the 10th centile had a subsequent fetal death, and 16% of those who had a positive angiogenic index-1 value at the 2.5th centile had a subsequent fetal death (Table 4 ). When weighting of cases and controls in the tested cohort was performed so that the weight of cases was the same as the prevalence of fetal death in the full cohort (0.4%, 17/ 4006), the risk of fetal death >24 weeks was determined to be 2% (PPV) for a positive angiogenic index-1 value at the 10th centile, and 6% (PPV) for a positive angiogenic index-1 value at the 2.5th centile. 
Placental lesions and fetal death
The placenta is considered to be a record of fetal life, 64 and by examining it histologically, one can often glean the intrauterine pathological processes that may have led to obstetrical complications such as fetal death. 32 The pathologic processes implicated in fetal death include: infection, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] 22 however, most of the 47,000 stillbirths reported by developed countries in 2015 149 were classified as unknown etiology. It is currently Angiogenic index-1 at 24-28 weeks in patients with subsequent fetal death For each fetal death case, data for 1 sample collected at 24-28 weeks are shown. Cases without placental lesions of maternal vascular underperfusion (MVU) (triangles) and cases with MVU (circles). Lines correspond with percentiles of angiogenic index-1 as described by labels in graph (2.5th, 10th, 50th, 90th, and 97.5th centiles). Distribution of raw longitudinal data used to derive percentiles is shown using heat map; color intensity denotes frequency of data points for corresponding gestational age and angiogenic index-1 value.
PlGF, placental growth factor; sVEGFR, soluble vascular endothelial growth factor receptor.
Chaiworapongsa et al. Angiogenic index-1 (PlGF/sVEGFR-1 ratio), biomarker for subsequent fetal death. Am J Obstet Gynecol 2017.
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believed that the causes of fetal loss change with gestational age: chromosomal abnormalities [150] [151] [152] [153] and infection 75 are the most common causes during the first half of pregnancy; placental issues (abruption or vascular abnormalities) [154] [155] [156] and maternal antifetal rejection 118 become the most common causes >26 weeks until term, 14 after which the etiology in most cases, especially >40 weeks, is unknown.
14 In this study, the frequency of placental lesions consistent with maternal vascular underperfusion was significantly higher in cases than controls, supporting the view that the most common cause of fetal death in the late second and third trimesters of pregnancy is placental in origin.
What is the association between fetal death and maternal plasma angiogenic index-1?
The placenta is a network of blood vessels surrounded by the trophoblast, 64 and the processes of vasculogenesis and angiogenesis are crucial for the success of pregnancy. Indeed, deletion of a single vascular endothelial growth factor allele in an embryo (haploinsufficiency) is lethal. 157 An imbalance in the maternal plasma angiogenic and antiangiogenic factors has been reported in women with preeclampsia 48, 55, 58, [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] an SGA neonate, 166, 169, 170, 173 and a subset of those who had a spontaneous preterm parturition, 174 mirror syndrome, [175] [176] [177] twin-to-twin transfusion syndrome, 178 and fetal death. 45, 46 These alterations in the maternal plasma concentrations of PlGF and sVEGFR-1 can be detected at the time of disease and at several weeks prior to the onset of the different obstetrical syndromes.
What are the clinical implications of a low maternal plasma angiogenic index-1?
In a previous study, 44 we reported that maternal plasma angiogenic index-1 measured at 30-34 weeks of gestation identified 80% of subsequent late fetal deaths. Among those who had a fetal death, identified by the maternal plasma angiogenic index-1 value, 80% had maternal vascular underperfusion. 44 This result, coupled with our findings that women who subsequently had a fetal death have higher maternal plasma sVEGFR-1 and lower PlGF concentrations, as early as 20 weeks of gestation, compared to those with a normal pregnancy, led us to explore whether the ratio between these 2 analytes was predictive of fetal death as early as 24 weeks of gestation. This study found that a maternal plasma angiogenic index-1 value <2.5th centile at 24-28 weeks of gestation (ie, <0.126) could identify 54.5% of subsequent fetal deaths. A patient whose plasma angiogenic index-1 at 24-28 weeks of gestation is <0.126 has a 6% chance of a fetal death, while a patient whose plasma angiogenic index-1 is >0.126 has only a 0.2% chance of a subsequent fetal death.
Two factors support choosing the 2.5th centile over the 10th centile as the cut-off Original Research OBSTETRICS ajog.org to define a positive angiogenic index-1. First, angiogenic index-1 is constant <2.5th centile but not <10th centile, so a single value can be used to determine whether a test is positive or negative using the 2.5th centile as the cut-off. Second, the proportion of false positives associated with preeclampsia or an SGA neonate was higher for false positives <2.5th centile (61%) than for the 10th centile (37%), making a positive result <2.5th centile more clinically significant than a positive result <10th centile, even if the latter cut-off is slightly more sensitive to predict a subsequent fetal death. A preliminary report indicating that statins may improve pregnancy outcome by reducing the antiangiogenic state in pregnancy 179 has increased the potential value of screening pregnancies for the PlGF/sVEGFR-1 concentration. We previously reported a case 179 in which a patient with recurrent fetal losses due to maternal perivillous fibrin deposition was successfully treated with pravastatin, and the treatment improved her PlGF/ sVEGFR-1 concentration ratio, leading to a successful pregnancy. Maternal perivillous fibrin deposition has a stereotypic pattern for angiogenic index-1, 180 and we provided evidence that this may reflect (at least, in some cases) maternal antifetal rejection. 120 Since treatment with pravastatin can reverse a low plasma PlGF/sVEGFR-1 concentration ratio, therapeutic trials of pravastatin in women who have a low plasma PlGF/sVEGFR-1 concentration ratio are warranted, especially given the negligible risks resulting from a falsepositive screening test result. Other interventions that could be effective include metformin 181 and proton pump inhibitors. 182, 183 Thus, the maternal plasma angiogenic index-1 value measured at 24-28 weeks of gestation can serve as a biomarker to identify women at risk of having a subsequent fetal death or developing other obstetrical complications. The availability of potentially effective treatments makes the formulation of practical screening programs using plasma angiogenic index-1 a clinical priority.
Strengths and limitations of this study
The strengths of this study are as follows. First, the use of a longitudinal casecohort study design included a random sample of about one quarter of the full cohort of 4006 women and all remaining women with a fetal death in the parent cohort. Unlike a nested case-control study, this case-cohort design allowed us to estimate RR and to account for other complications that may involve a common pathway with fetal death. Second, we demonstrated that an angiogenic index-1 value <2.5th centile has a higher positive likelihood ratio for patients whose placenta had histologic lesions of maternal vascular underperfusion, emphasizing that this riskassessment method is also related to the underlying mechanism of disease leading to fetal death. Finally, the proportion of placental-associated fetal deaths in this study is comparable to that reported in another study. 34 Limitations of this study are as follows. First, in the study design, the subcohort of 1000 random individuals was not selected completely at random from the full cohort but rather from all patients who had at least 3 blood samples available for analysis. Such longitudinal data are best suited for establishing reference intervals in the control group. Second, not all of the patients selected for inclusion in the case cohort provided a sample during the 24-to 28-week interval for analysis. Third, the small number of late fetal deaths included in the analysis is a limitation; however, this reflects the prevalence of the disease in the population, and, in spite of this, we demonstrated a highly positive result. Finally, although an abnormal angiogenic index-1 value had the highest RR and positive likelihood ratio for fetal death, a cost-effectiveness analysis is still warranted to determine the optimal screening method, since sEng (Figure 1 , B) alone had a similar prediction performance for this outcome.
Conclusions
First, a maternal plasma angiogenic index-1 value <2.5th centile at 24-28 weeks of gestation carries a 29-fold increase for the risk of subsequent fetal death and identifies 55% of these patients at a very low (3.7%) false-positive rate. Second, 61% of the women who had a false-positive result subsequently had adverse pregnancy outcomes (preeclampsia or an SGA neonate). n ajog.org
